Saksagliptin ve Sitagliptinin Farklı Tip İnsan Kanser HücreCanlığı Üzerine Etkilerinin Araştırılması
Yükleniyor...
Dosyalar
Tarih
2017
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Fırat Üniversitesi Sağlık Bilimleri Tıp Dergisi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Öz: Amaç: İnkretin hormonlar hipoglisemik gastrointestinal hormon grubunda yer almaktadır. Dipeptidil peptidaz-4 enzimi (DPP-4) ise inkretinleri inaktive etmektedir. DPP-4 inhibitörleri inkreatinlerin'in yıkılmasını engelleyerek artan kan glukozunu dengelemektedir. Saksagliptin ve sitagliptin bu ailenin (DPP-4 inhibitör) yeni üyeleridir. DPP-4 inhibitörlerinin kan glukoz seviyesi üzerine etkileri dışında antioksidan ve anti-inflamatuar etkilerinin olduğu bildirilmiştir. Bu çalışma DPP-4 inhibitör ailesinin üyeleri olan saksagliptin ve sitagliptin anti-kanser özelliklerini araştırmak amacıyla yapıldı. Gereç ve Yöntem: Çalışmada insan over (A2780), insan meme (MCF-7) ve insan prostat (PC-3 ve LNCaP) kanseri hücre hatları kullanıldı. Tüm hücre hatlarına saksagliptin ve sitagliptinin 1, 5, 25, 50 ve 100 ?g/mL'lik konsantrasyonlarının 24 saat süreyle hücre canlılığında meydana gelen değişimler 3-(4,5-dimetiltiazol-2-il)-2,5-difeniltetrazolyum bromid (MTT) assay yöntemiyle belirlendi. MTT assay sonuçlarına göre inhibe edici konsantrasyon 50 (LogIC50) değeri Graphpad prism 6 programında hesaplandı. Bulgular: 24 saat süreyle kanser hücreleri (A2780, MCF-7, PC-3 ve LNCaP) ile inkübe edilen sitagliptin ve saksagliptinin kanser hücre canlılığında önemli azalmalara eden olduğu belirlendi (P<0.05). Sonuç: Bu çalışmanın sonuçları, test edilen saksagliptin ve sitagliptinin A2780, MCF-7, PC-3 ve LNCaP hücreleri üzerine antitümör aktiviteye sahip olduğunu göstermektedir.
Abstract: Objective: Incretin hormones are classified in hypoglycemic gastrointestinal hormone group. Dipeptidyl peptidase-4 enzyme (DPP-4) inactivates incretins. DPP-4 inhibitors prevent the collapse of incretins and balance the increasing blood glucose. Saxagliptin and sitagliptin are the new members of this family (DPP-4 inhibitor). It was reported that the DPP-4 inhibitors have effects on blood glucose levels, and they also have antioxidant and anti-inflammatory effects. This study was conducted to investigate the anti-cancer properties of saxagliptin and sitagliptin, which are the members of DPP-4 inhibitor family. Materials & Methods: The human ovary (A2780), human breast (MCF-7) and human prostate (PC-3 and LNCaP) cancer cell lines were used in the study. The changes occurring in the cell viability for 24 h in all cell lines in 1, 5, 25, 50 and 100 ?g/mL of saxagliptin and sitagliptin 1, 5, 25, 50 and 100 ?g/mL concentrations were determined with the 3-(4,5-dimethylimidazole-2-il)-2,5diphenyltetrazolium bromide (MTT) assay method. According to the MTT assay results, the inhibiting concentration 50 (LogIC50) value was calculated in the Graphpad Prism 6 Program. Results: It was determined that the sitagliptin and saxagliptin that were incubated with cancer cells (A2780, MCF-7, PC-3 and LNCaP) for 24 h caused significant decreases in the viability of the cancer cells (P<0.05). Conclusion: The results of the present study show that the saxagliptin and sitagliptin, which were tested, have antitumor activity on A2780, MCF-7, PC-3 and LNCaP cells.
Abstract: Objective: Incretin hormones are classified in hypoglycemic gastrointestinal hormone group. Dipeptidyl peptidase-4 enzyme (DPP-4) inactivates incretins. DPP-4 inhibitors prevent the collapse of incretins and balance the increasing blood glucose. Saxagliptin and sitagliptin are the new members of this family (DPP-4 inhibitor). It was reported that the DPP-4 inhibitors have effects on blood glucose levels, and they also have antioxidant and anti-inflammatory effects. This study was conducted to investigate the anti-cancer properties of saxagliptin and sitagliptin, which are the members of DPP-4 inhibitor family. Materials & Methods: The human ovary (A2780), human breast (MCF-7) and human prostate (PC-3 and LNCaP) cancer cell lines were used in the study. The changes occurring in the cell viability for 24 h in all cell lines in 1, 5, 25, 50 and 100 ?g/mL of saxagliptin and sitagliptin 1, 5, 25, 50 and 100 ?g/mL concentrations were determined with the 3-(4,5-dimethylimidazole-2-il)-2,5diphenyltetrazolium bromide (MTT) assay method. According to the MTT assay results, the inhibiting concentration 50 (LogIC50) value was calculated in the Graphpad Prism 6 Program. Results: It was determined that the sitagliptin and saxagliptin that were incubated with cancer cells (A2780, MCF-7, PC-3 and LNCaP) for 24 h caused significant decreases in the viability of the cancer cells (P<0.05). Conclusion: The results of the present study show that the saxagliptin and sitagliptin, which were tested, have antitumor activity on A2780, MCF-7, PC-3 and LNCaP cells.
Açıklama
Anahtar Kelimeler
Kaynak
Fırat Üniversitesi Sağlık Bilimleri Tıp Dergisi
WoS Q Değeri
Scopus Q Değeri
Cilt
31
Sayı
3
Künye
TEKİN S,BEYTUR A,ÇAKIR M,TEKİN Ç,SANDAL S (2017). Saksagliptin ve Sitagliptinin Farklı Tip İnsan Kanser Hücre Canlığı Üzerine Etkilerinin Araştırılması. Fırat Üniversitesi Sağlık Bilimleri Tıp Dergisi, 31(3),111 - 116.
